Results 41 to 50 of about 61,341 (287)

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial [PDF]

, 2016
Introduction: Diabetes mellitus affects 9% of the European population and accounts for 15% of healthcare expenditure, in particular, due to excess costs related to complications.
Beige, Joachim, Currie, Gemma, Delles, Christian, Lindhardt, Morten, Mischak, Harald, Navis, Gerjan, Noutsou, Marina, Ortiz, Alberto, Persson, Frederik, Pontillo, Claudia, Rossing, Peter, Ruggenenti, Piero Luigi, Rychlik, Ivan, Spasovski, Goce, von der Leyen, Heiko   +14 more
core   +4 more sources

Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure

Arquivos Brasileiros de Cardiologia, 2015
Background: Matrix metalloproteinases (MMPs) are a family of enzymes important for the resorption of extracellular matrices, control of vascular remodeling and repair.
João Pedro Ferreira, Mário Santos, José Carlos Oliveira, Irene Marques, Paulo Bettencourt, Henrique Carvalho   +5 more
doaj   +1 more source

Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model [PDF]

Diabetes & Metabolism Journal, 2011
BackgroundWhile there is an evidence that the anti-inflammatory properties of spironolactone can attenuate proteinuria in type 2 diabetes, its effects on vascular endothelial growth factor (VEGF) expression in diabetic nephropathy have not been clearly ...
Mi Young Lee, Myoung Sook Shim, Bo Hwan Kim, Soon Won Hong, Ran Choi, Eun Young Lee, Soo Min Nam, Gun Woo Kim, Jang Yel Shin, Young Goo Shin, Choon Hee Chung   +10 more
doaj   +1 more source

Pharmacologic inhibition by spironolactone attenuates experimental abdominal aortic aneurysms

Frontiers in Cardiovascular Medicine, 2023
BackgroundAbdominal aortic aneurysms (AAA) are characterized by vascular inflammation and remodeling that can lead to aortic rupture resulting in significant mortality. Pannexin-1 channels on endothelial cells (ECs) can modulate ATP secretion to regulate
Zachary Ladd, Gang Su, Joseph Hartman, Guanyi Lu, Sara Hensley, Gilbert R. Upchurch, Ashish K. Sharma   +6 more
doaj   +1 more source

Amiloride reduces portal hypertension in rat liver cirrhosis [PDF]

, 2010
Objective This study aimed to investigate the effect of amiloride on portal hypertension. Amiloride is known to inhibit Na(+)/H(+) exchangers on activated hepatic stellate cells.
Beitinger, Frigga, Bystron, Markus, De Toni, Enrico N., Gerbes, Alexander L., Hartmann, Anna C., Hennenberg, Martin, Steib, Christian J.   +6 more
core   +1 more source

Spironolactone for heart failure with preserved ejection fraction.

New England Journal of Medicine, 2014
BACKGROUND Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction.
B. Pitt, M. Pfeffer, S. Assmann, R. Boineau, I. Anand, Brian Claggett, N. Clausell, Akshay S. Desai, R. Diaz, J. Fleg, I. Gordeev, B. Harty, J. Heitner, C. Kenwood, E. Lewis, E. O’Meara, J. Probstfield, T. Shaburishvili, Sanjiv J. Shah, S. Solomon, N. Sweitzer, Song Yang, S. Mckinlay   +22 more
semanticscholar   +1 more source

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial

European Heart Journal, 2020
Aims  To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure. Methods and results  Randomized, open-label, blinded-endpoint trial comparing spironolactone (50 mg/day) or ...
J. Cleland, J. Ferreira, B. Mariottoni, P. Pellicori, J. Cuthbert, J. Verdonschot, J. Petutschnigg, F. Ahmed, F. Cosmi, Hans-Peter Brunner la Rocca, M. Mamas, A. Clark, F. Edelmann, B. Pieske, J. Khan, K. McDonald, P. Rouet, J. Staessen, B. Mujaj, Arantxa González, J. Díez, M. Hazebroek, S. Heymans, R. Latini, S. Grojean, A. Pizard, N. Girerd, P. Rossignol, T. Collier, F. Zannad   +29 more
semanticscholar   +1 more source

Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
BACKGROUND Uncontrolled blood pressure (BP) increases the risk of developing heart failure (HF). The effect of spironolactone on BP of patients at risk of developing HF is yet to be determined. AIMS To evaluate the effect of spironolactone on the BP of
J. Ferreira, T. Collier, A. Clark, M. Mamas, H. Rocca, S. Heymans, Arantxa González, F. Ahmed, J. Petutschnigg, B. Mujaj, J. Cuthbert, P. Rouet, P. Pellicori, B. Mariottoni, F. Cosmi, F. Edelmann, L. Thijs, J. Staessen, M. Hazebroek, J. Verdonschot, P. Rossignol, N. Girerd, J. Cleland, F. Zannad   +23 more
semanticscholar   +1 more source

The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment [PDF]

, 2003
National surveys suggest that treatment of heart failure in daily practice differs from guidelines and is characterized by underuse of recommended medications.
Aguilar, JC, Cleland, J, Cohen-Solal, A, Dietz, R, Eastaugh, J, Follath, F, Freemantle, N, Gavazzi, A, Hobbs, R, Komajda, M, Korewicki, J, Madeira, HC, Mason, J, Moiseyev, VS, Preda, I, Swedberg, K, Van Gilst, WH, Widimsky, J   +17 more
core   +5 more sources

Efficacy and Safety of Spironolactone in the Treatment of Resistant Hypertension：a Meta-analysis [PDF]

Zhongguo quanke yixue, 2022
BackgroundAs a special type of hypertension, resistant hypertension has complex etiology, is difficult to treat, and more likely to lead to target organ damage.
ZHANG Ping, ZOU Jing, GAO Cunzhou, WU Aiping, LI Rongshan
doaj   +1 more source